American Securities takes majority stake in Simonmed Imaging

UNITED STATES Health Providers / Outpatient Care / Radiology EV $500M–1.5bn

Context

SimonMed Imaging has entered into a strategic partnership with American Securities, a leading US private equity firm, as part of a growth investment aimed at supporting the company's next phase of expansion. Following the transaction, American Securities has become a shareholder of SimonMed alongside the company's founder and CEO, Dr. John Simon, who retains a central role in the company's governance and strategic direction. This partnership comes at a time of significant growth in the US outpatient medical imaging market, driven by the increasing shift of diagnostic exams from hospitals to specialized centers offering lower-cost services. American Securities was attracted to SimonMed's unique positioning, which combines the operation of imaging centers with in-house radiologist interpretation, as well as its ability to offer competitive pricing. With this investment, SimonMed aims to accelerate its organic and inorganic growth by strengthening its presence in existing markets and pursuing expansion into new regions across the US. The capital injection will also enable the company to invest further in cutting-edge imaging equipment, artificial intelligence solutions for medical diagnosis, and enhanced patient experience initiatives.

Simonmed Imaging, which reported an EBITDA margin of [members only] in 2020, is valued in this transaction at an EV/EBITDA multiple of 5x–12x.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2002 by Dr. John Simon and headquartered in Scottsdale, Arizona, SimonMed Imaging is one of the largest independent outpatient medical imaging networks and a leading radiology group in the United States. The company operates over 160 imaging centers across 11 states, performing nearly two million exams annually. Its integrated model combines direct ownership of imaging centers with the employment of specialized radiologists who interpret exams, enabling complete control over the diagnostic value chain. SimonMed offers a comprehensive range of diagnostic imaging services, including MRI, CT scans, ultrasound, 3D mammography, PET/CT, nuclear medicine, DEXA scans, and conventional radiography. The group differentiates itself through its focus on affordable healthcare, utilization of state-of-the-art equipment, and deployment of subspecialized radiologists to enhance diagnostic quality. With over 2,200 employees, including approximately 200 radiologists, SimonMed has established itself as a leading provider of community-based medical imaging services in the United States.

Ent. Value

$500M–1.5bn

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

5x–12x

EV / EBIT

[members only]

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2020

2019

Other operations with American Securities

Other operations with American Securities
Date	Acquirer	Target	Country	Sector
04/2020	AMERICAN SECURITIES	PARAGON MEDICAL	UNITED STATES	Medical Devices

Similar deals in Health Providers

Similar deals in Health Providers
Date	Acquirer	Target	Country	Sector
07/2021	OMERS	AMEDES	GERMANY	Labs (Biology)
05/2021	INFRATIL	PACIFIC RADIOLOGY GROUP	NEW ZEALAND	Radiology
04/2021	ICG / MANAGEMENT & PRIVATE INVESTORS	DOMUSVI	FRANCE	Nursing Homes
03/2021	EQT PARTNERS	CERBA HEALTHCARE	FRANCE	Labs (Biology)
03/2021	TRITON PARTNERS	BERGMAN CLINICS	NETHERLANDS	Clinics / Hospitals
02/2021	SILVER LAKE / NESTLE	IVC EVIDENSIA	UNITED KINGDOM	Vet Clinics
12/2020	RADIOLOGY PARTNERS	MEDNAX RADIOLOGY SOLUTIONS	UNITED STATES	Radiology
12/2020	FRESENIUS	EUGIN GROUP	SPAIN	Outpatient Care
12/2020	ANTIN INFRASTRUCTURE	HIPPOCRATES (LAF - LA FARMACIA)	ITALY	Pharmacy
12/2020	MEDIAN KLINIKEN	PRIORY GROUP	UNITED KINGDOM	Clinics / Hospitals

REFERENCES

Valuation range: EV $500M–1.5bn

EBITDA range: $50–100M

EV/EBITDA range: 5x - 12x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Simonmed Imaging by American Securities are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: simonmed imaging

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Simonmed Imaging, an American company specialised in Outpatient Care, by American Securities in 2021, structured as a leveraged buyout (LBO).

How was the acquisition of Simonmed Imaging by American Securities valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the $500M–1.5bn band and its EV/EBITDA multiple within the 5x - 12x range. Exact figures are available to members.

What was Simonmed Imaging’s EBITDA at the time of the deal?

At the time of the transaction, Simonmed Imaging’s EBITDA was estimated within the $50–100M bracket (FY 2020). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction intelligence is supported by independent reporting from specialized financial publications, alongside a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.